Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 4/20 | 0.50 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.50 |
| ▸ | MAOB | P27338 | 3/20 | 0.45 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.45 |
| ▸ | MAOA | P21397 | 2/20 | 0.45 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.45 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.45 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.45 |
| ▸ | CHAT | P28329 | 1/20 | 0.45 |
| ▸ | DPP4 | P27487 | 1/20 | 0.42 |
| ▸ | DHFR | P00374 | 1/20 | 0.40 |
| ▸ | PNMT | P11086 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20124829 | 1.00 | NFE2L2 (0.50) | NFE2L2TRPA1MAOBCYP19A1MAOA | |
| SCHEMBL27969283 | 1.00 | NFE2L2 (0.50) | NFE2L2TRPA1MAOBCYP19A1MAOA | |
| SCHEMBL27978369 | 0.86 | LOXL2 (0.41) | NFE2L2TRPA1MAOBCYP19A1MAOA | |
| SCHEMBL28130350 | 0.86 | LOXL2 (0.41) | NFE2L2TRPA1MAOBCYP19A1MAOA | |
| SCHEMBL10765758 | 0.84 | NFE2L2 (0.52) | NFE2L2TRPA1MAOBCYP19A1MAOA | |
| SCHEMBL10765753 | 0.84 | NFE2L2 (0.52) | NFE2L2TRPA1MAOBCYP19A1MAOA | |
| SCHEMBL27978430 | 0.82 | LOXL2 (0.42) | NFE2L2TRPA1MAOBCYP19A1MAOA | |
| SCHEMBL27969100 | 0.82 | LOXL2 (0.42) | NFE2L2TRPA1MAOBCYP19A1MAOA | |
| SCHEMBL10761271 | 0.81 | NFE2L2 (0.48) | NFE2L2TRPA1MAOBCYP19A1MAOA | |
| SCHEMBL10761275 | 0.81 | NFE2L2 (0.48) | NFE2L2TRPA1MAOBCYP19A1MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102061161-A | Gadolinium-doped liquid scintillator | INST HIGH ENERGY PHYSICS CAS | 2011-05-18 | — | — | CN | claimed |
| EP-1904069-B1 | ARYL-AND HETEROARYL-SUBSTITUTED TETRAHYDROBENZAZEPINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN | ALBANY MOLECULAR RES INC (US) | 2018-06-13 | — | — | EP | disclosed |
| CN-103947031-B | Organic electrolyte and organic electrolyte secondary battery | 吉坤日矿日石能源株式会社 | 2017-07-11 | — | — | CN | disclosed |
| US-9403776-B2 | Aryl- and heteroaryl-substituted tetrahydrobenzazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin | ALBANY MOLECULAR RESEARCH, INC. (US) | 2016-08-02 | — | — | US | disclosed |
| US-20140296514-A1 | ARYL- AND HETEROARYL-SUBSTITUTED TETRAHYDROBENZAZEPINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN | APOLLO ADMINISTRATIVE AGENCY LLC, AS SUCCESSOR AGENT | 2014-10-02 | — | — | US | disclosed |
| CN-102203100-B | Cephalosporin with catechol group | SHIONOGI & CO | 2014-08-27 | — | — | CN | disclosed |
| US-8791101-B2 | Aryl- and heteroaryl-substituted tetrahydrobenzazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin | ALBANY MOLECULAR RESEARCH, INC. (US) | 2014-07-29 | — | — | US | disclosed |
| CN-103947031-A | Organic electrolyte and organic electrolyte secondary battery | JX NIPPON OIL & ENERGY CORP | 2014-07-23 | — | — | CN | disclosed |
| CN-102918048-A | Cephem compounds having catechol group | SHIONOGI & CO | 2013-02-06 | — | — | CN | disclosed |
| CN-102918047-A | Cephem compound having pseudo-catechol group | SHIONOGI & CO | 2013-02-06 | — | — | CN | disclosed |
| WO-2007011820-A2 | ARYL-AND HETEROARYL-SUBSTITUTED TETRAHYDROBENZAZEPINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN | AMR TECHNOLOGY, INC. (US) | 2007-01-25 | — | — | WO | disclosed |
| CN-1333776-A | Imidazo [4, 5-b ] pyridiniummethyl-containing cephem compounds having broad-spectrum antibacterial activity | SHIONOGI & CO (JP) | 2002-01-30 | — | — | CN | disclosed |
| CN-1030656-C | Process of producing sulfonylureas | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1996-01-10 | — | — | CN | disclosed |
| CN-1029405-C | Lipid A analogs having immunoactivating and anti-tumor activity | SANKYO CO (JP) | 1995-08-02 | — | — | CN | disclosed |
| CN-1018643-B | Process for producing sulfonylurea compound | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1992-10-14 | — | — | CN | disclosed |
| CN-1052481-A | Lipoid category-A with immunocompetence and anti-tumor activity is like thing | SANKYO CO (JP) | 1991-06-26 | — | — | CN | disclosed |
| CN-1032010-A | The method for preparing sulfonyl urea derivates | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1989-03-29 | — | — | CN | disclosed |
| CN-87102123-A | Sulfonylurea compounds, their preparation and their use as herbicides | — | 1987-10-21 | — | — | CN | disclosed |
| CN-85105299-A | The preparation method of cephem compounds | — | 1987-01-07 | — | — | CN | disclosed |
| CN-85105797-A | The preparation of antimicrobial compounds | — | 1986-08-27 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140296514-A1 | ARYL- AND HETEROARYL-SUBSTITUTED TETRAHYDROBENZAZEPINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN | ADRA2B, ADRA2C, HTR2B | NFE2L2 1739/4885TRPA1 1376/4885MAOB 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.